MRS2 and metabolic dysfunction-associated steatohepatitis: These results indicated that serum Fuc-Hpt levels cannot be used to distinguish NASH from CHC patients with advanced fibrosis, but could be a useful biomarker for the discrimination of NASH patients with early liver fibrosis.